.Pharmacolibrary.Drugs.ATC.L.L03AX16_1 .Pharmacolibrary.Drugs.ATC.L.L03AX16_1| name: | Plerixafor_1 | |
| ATC code: | L03AX16_1 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 240 | mg |
| volume of distribution: | 0.3 | L |
| clearance: | 0.08 | L/h/kg |
| other parameters in model implementation | ||
Plerixafor is a hematopoietic stem cell mobilizer that acts as a CXCR4 antagonist. It is used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Plerixafor is currently approved by regulatory agencies such as FDA and EMA for this indication.
Pharmacokinetic parameters in patients with varying degrees of renal impairment; after a single subcutaneous injection.
Cashen, A, et al., & DiPersio, J (2008). A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 14(11) 1253–1261. DOI:10.1016/j.bbmt.2008.08.011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18940680
Lack, NA, et al., & Bridger, G (2005). A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clinical pharmacology and therapeutics 77(5) 427–436. DOI:10.1016/j.clpt.2004.12.268 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15900288